collaboration criving innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Search
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Scleroderma
Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs
How dangerous is the mpox virus?
Mpox, formerly known as monkeypox: What exactly is this virus, how is it transmitted, and what are the most noticeable symptoms?
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
EMPRISE
Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care
The little things
In 2009 Anna was diagnosed with scleroderma. For her, however, the disease is no reason to give up. On the contrary.
Embracing diversity in clinical trials
At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
vet scholars symposium
Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
Bringing Precision to Psychiatry
Dr. Hugh Marston discusses how precision psychiatry can enable people living with mental health conditions to thrive.
EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
EMPRISE-Study
EMPRISE-Study
New spesolimab data show significant improvement in GPP flares
New spesolimab data show significant improvement in GPP flares
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
Breakthrough Designation granted in US and China
SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
Spesolimab meets key endpoint for GPP flare prevention
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
CHMP recommends conditional approval for first GPP treatment
CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Spesolimab Phase II data
New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares